Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Siemens Medical/Shared Medical Systems

This article was originally published in The Gray Sheet

Executive Summary

Siemens appoints Francis Lavelle president and CEO of SMS, effective Aug. 11. Lavelle previously served as VP-U.S. customer operations at SMS, which was acquired by Siemens in May (1"The Gray Sheet" May 8, p. 3). Management shift occurs following resignation of current President and CEO Marvin Caldwell. Hans Mehl, former managing director Siemens audiological engineering division, replaces Terrence Kyle as senior-VP finance. Siemens announces formation of an integration team with members from both firms to "unite the expertise and strengths of both organizations"

You may also be interested in...



Siemens' $2.1 Bil. SMS Buy To Leverage 10% Annual Health Care IT Growth

Acquisition of health information systems and services provider Shared Medical Systems for $2.1 bil. in cash will help Siemens Medical Engineering Group capitalize on the estimated 10% annual growth of the health care information technology sector and build on its strategy to increase the services component of its business from 25% to 50%, Siemens says.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel